Abstract: The present invention relates to a method of eliciting a cytotoxic T lymphocyte response to an antigen in an animal, the method comprising pulsing mannose receptor-bearing antigen presenting cells in vitro or ex vivo with a conjugate comprising an antigen and a carbohydrate polymer comprising mannose, wherein said carbohydrate polymer is a fully oxidized carbohydrate polymer comprising free aldehydes; and administering the pulsed antigen presenting cells to an animal.

Abstract: The present invention relates to an immunogenic composition comprising a conjugate between an antigen and an oxidized mannan comprising mannose units and aldehyde groups, and a pharmaceutically acceptable carrier.

Abstract: This invention relates to a method of inhibiting Fc receptor binding of immunoglobulin including the use of a Fc receptor modulating compound which binds to defined surfaces on a Fc receptor. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating compound.

Abstract: Disclosed are crystals, crystal structure Fc&ggr;RIIa protein, three dimensional coordinates of Fc&ggr;RIIa protein, and structures and models derived from the Fc&ggr;RIIa structure. Also disclosed are crystals of Fc&egr;RI protein and three dimensional coordinates of Fc&egr;RI protein monomers and dimers derived from the Fc&ggr;RIIa structure. Also disclosed are three dimensional coordinates of Fc&ggr;RIIIb proteins and models of Fc&ggr;RIIIb derived from the Fc&ggr;RIIa structure. The present invention also includes methods to produce such crystals, crystal structures and models. Uses of such crystals, crystal structures and models are also disclosed, including structure based drug design and therapeutic compositions.

Abstract: Disclosed are crystals, crystal structure Fc&ggr;RIIa protein, three dimensional coordinates of Fc&ggr;RIIa protein, and structures and models derived from the Fc&ggr;RIIa structure. Also disclosed are crystals of Fc&egr;RI protein and three dimensional coordinates of Fc&egr;RI protein monomers and dimers derived from the Fc&ggr;RIIa structure. Also disclosed are three dimensional coordinates of Fc&ggr;RIIIb proteins and models of Fc&ggr;RIIIb derived from the Fc&ggr;RIIa structure. The present invention also includes methods to produce such crystals, crystal structures and models. Uses of such crystals, crystal structures and models are also disclosed, including structure based drug design and therapeutic compositions.

Abstract: Conjugates between whole antigen or one or more repeated subunits of an antigen and a carbohydrate polymer are described. Also described are immunogenic vaccines against disease states which contain the conjugates and methods for inducing cell-mediated immune responses. The conjugates may especially contain polymers of the carbohydrate mannose and one or more repeated subunits of human mucin or non-repeated regions of human mucin.

Abstract: The present invention relates to methods and compositions for the reduction of xenotransplantation rejection. Specifically, the present invention relates, first, to transgenic cells, tissues, organs and animals containing transgenic nucleic acid molecules that direct the expression of gene products, including, but not limited to enzymes, capable of modifying, either directly or indirectly, cell surface carbohydrate epitopes such that the carbohydrate epitopes are no longer recognized by natural human antibodies or by the human cell-mediated immune response, thereby reducing the human immune system response elicited by the presence of such carbohydrate epitopes. In a preferred embodiment, the transgenic cells, tissues, organs and animals express nucleic acid molecules encoding functional recombinant &agr;-Galactosidase A (&agr;GalA) enzyme which modifies the carbohydrate epitope Gal&agr;(1,3)Gal.

Abstract: Disclosed are crystals, crystal structure Fc&ggr;RIIa protein, three dimensional coordinates of Fc&ggr;RIIa protein, and structures and models derived from the Fc&ggr;RIIa structure. Also disclosed are crystals of Fc&egr;RI protein and three dimensional coordinates of Fc&egr;RI protein monomers and dimers derived from the Fc&ggr;RIIa structure. Also disclosed are three dimensional coordinates of Fc&ggr;RIIIb proteins and models of Fc&ggr;RIIIb derived from the Fc&ggr;RIIa structure. The present invention also includes methods to produce such crystals, crystal structures and models. Uses of such crystals, crystal structures and models are also disclosed, including structure based drug design and therapeutic compositions.

Abstract: Conjugates between one or more repeated subunits of an antigen and a carbohydrate polymer are desired. Also described are immunogenic vaccines against disease states which contain the conjugates and methods for inducing cell-mediated immune responses. The conjugates may especially contain polymers of the carbohydrate mannose and one or more repeated subunits of human mucin.

Abstract: Method of increasing protein production in a host cell where the nucleic acid encoding the protein has an A and/or T rich region in an exon. The method comprising lowering the amount of A and/or T rich region and transfecting a host cell with the altered nucleic acid and obtaining expression of the nucleic acid. The invention also relates to the recombinant nucleic acid constructs, purified protein preparations and pharmaceutical compositions produced as well as methods of treatment utilizing the purified protein preparation.

Abstract: Conjugates between one or more repeated subunits of an antigen and a carbohydrate polymer are desired. Also described are immunogenic vaccines against disease states which contain the conjugates and methods for inducing cell-mediated immune responses. The conjugates may especially contain polymers of the carbohydrate mannose and one or more repeated subunits of human mucin.

Abstract: Nucleotide sequences encoding a protein with Fc receptor activity or a fragment thereof that is capable of binding the Fc region of immunoglobulin and polypeptides with Fc receptor activity are provided. Proteins which exhibit enhanced or reduced immunoglobulin binding ability relative to native Fc receptors and nucleotides encoding these proteins also are provided. The invention also provides methods of determining the presence of immunoglobulin, detecting an immune complex, removing immunoglobulin from a body fluid and treating disease using the proteins.

Abstract: DNA sequences encoding a porcine Gal.alpha.(1,3) galactosyl transferase and clones containing such sequences are provided. The porcine Gal.alpha.(1,3) galactosyl transferase produces the Gal.alpha.(1,3)Gal epitope on the surfaces of porcine cells. This epitope is recognized by human anti-Gal.alpha.(1,3)Gal antibodies which are responsible for hyperacute rejection of xenotransplanted pig cells, tissues and organs.

Abstract: A receptor for the Fc portion of immunoglobulin, derived from mouse or human cells, the receptor exhibiting the ability to bind to the Fc portion of mouse and human immunoglobulin and comprising a transmembrane proteins having about 280-301 amino acids including two substantially regularly spaced pairs of Cys residues and two or four potential N-linked glycosylation sites. The present invention also provides for a nucleotide sequence, gene, cDNA clone or a vector containing same capable of encoding the above receptor.

Abstract: A method for identifying and/or determining the location of a tumor which produces or is associated with a cytoplasmic, intra-cellular or cell surface marker substance, is disclosed, which comprises the steps of:(a) injecting a human or animal subject with tumor specific antibody or a fragment thereof specific for the marker and labelled with a radioactive isotope of an element or a paramagnetic conjugate; and an irrelevant (non-tumor reactive) antibody which has been labelled with a non-radioactive isotope of the same or other element, or a non-paramagnetic conjugate; and(b) after a period of time sufficient for selective binding of the labelled tumor specific antibody to the tumor scanning the human or animal subject with a detector to locate the site or sites of uptake of labelled antibody or fragments thereof.Imaging compositions are also described.

Abstract: A compound of formula I ##STR1## wherein R.sub.1 is of formula II ##STR2## wherein R.sub.4 and R.sub.5, which may be the same or different, are bromo, chloro, iodo or alkylsulphonyl;R.sub.2 is of formula III ##STR3## wherein R.sub.6 and R.sub.7, which may be the same or different, are H, alkyl, aryl, carboxy, hydroxy or amino and n is 0-10; andR.sub.3 is hydroxy or a group capable of being cleared and replaced by a radical having an antigen binding site or R.sub.3 is a radical having an antigen binding site.

Abstract: A method for testing for the HLA-B27 antigen which comprises mixing with blood cells or blood cell lysates a first antibody capable of binding and blocking the HLA-B7 antigen and a second antibody capable of binding to the HLA-B27 antigen wherein said second antibody is labelled so as to be detectable and thereafter detecting for the said labelled second antibody. The second antibody is specific to the HLA-B27 antigen. It is found that the HLA-B7 antigen binds in significant quantities to the second antibody. Therefore it is necessary to block the HLA-B7 antigen with said first antibody.